Safety Issues, Tolerance
Conditions
Keywords
PK, Efficacy
Brief summary
Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766 in Healthy participants.
Detailed description
Study Design: This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose ascending study in healthy participants with concurrent pharmacokinetic (PK) sampling from blood plasma, urine, and cerebrospinal fluid. The overall study design is outlined below: Part 1: Single-Dose Regimen and Fasted-Fed Crossover. For the single-dose regimen, approximately 40 healthy male or female participants will be enrolled in 1 of 5 single-dose cohorts (designated as S1 through S5, respectively) in an ascending fashion. Each cohort will consist of 8 participants randomized to CVN766 or placebo, whereby 6 participants will receive a single oral dose of CVN766 suspension, and 2 participants will receive a matching placebo suspension under overnight fasted conditions. Participants will remain fasted for 4 hours post-dose. Consumption of water is permitted as desired except for 1 hour before and after administration of Study Drug. Sentinel dosing (1 participant to receive CVN766 and 1 participant to receive placebo) will be used in each cohort to ensure adequate safety and tolerability evaluation prior to administering CVN766 or placebo to the remainder of participants within the cohort. After blinded review by the Safety Review Group (SRG) of 24-hours, post-dose safety and tolerability data from the sentinel group, the remaining 6 participants of each cohort may be dosed provided that the adverse event (AE) profile in the first 2 participants is considered acceptable. To accommodate the lumbar puncture in the S3 fasted cohort, after the sentinel group, the remaining 6 participants dosing may be staggered every two days. The planned dose levels will be 5, 15, 45, 125, and 250 mg CVN766. The SRG will review all available blinded safety, tolerability, clinical laboratory results (minimally including samples collected from participants through 72-hours post-dose), and PK data after each cohort and before subsequent dose escalation. Each following dose level may be higher, lower, or remain the same as the preceding cohort, dependent on the recommendation of the SRG. Additional cohort(s) may be added if deemed necessary by the SRG to fully characterize the safety and tolerability of CVN766. For example, if the maximum tolerated dose (MTD) is not reached with cohort S5, additional cohorts with higher dose levels may be considered. Such additional cohorts will follow the same schedule of events as cohorts S1 through S5. Additional/alternative PK timepoints may be implemented if the SRG determines this is necessary to fully characterize the PK profile of CVN766. To assess the effect of food on CVN766 bioavailability in suspension formulation, single-dose administration will be repeated in a single cohort (S3) after ingestion of a standardized high-fat, high-calorie meal according to FDA Guidance for Industry (Food-effect bioavailability and fed bioequivalence studies, Dec 2002). Once the safety of the S3 cohort dose level has been assessed, the S3 cohort participants will return to the clinic (no sooner than 14 days after their prior dose, or at least 4 half-lives, has lapsed based on preliminary PK data, whichever is longer). They will receive the same dose as before, administered after ingesting a standardized breakfast. Participants will finish the entire content of their breakfast within 25 minutes and will receive CVN766 30 minutes (± 5 minutes) after beginning the meal. Sentinel dosing will not be required for participants returning to the clinic for the fed regimen. If the CVN766 PK parameters in the fasted S3 cohort reveal poor absorption with inconclusive results, the fed cohort will be deferred until a higher dose level. Participants for all cohorts will be admitted to the study unit 1 day prior to dosing and remain in the unit for safety and PK assessments. On Day 1, participants will undergo safety monitoring and PK sampling from blood plasma through 72 hours post-dose and, for cohort S3 (fasted) only, from CSF via lumbar puncture at 3 hours post-dose. The total confinement period will be 4 nights, unless extended at the discretion of the Investigator, e.g., for monitoring and/or management of AEs. Follow-up assessments will occur on approximately Days 8 and 14 and +21 and +28 for cohort S3. Part 2: Multiple-Dose Regimen. For the multiple-dose regimen, approximately 24 healthy male and female participants age 18 to 50 years old will be enrolled in 1 of the 3 multiple-dose cohorts (designated as M1 through M3, respectively) in an ascending fashion. The dose levels planned to be studied in the multiple-dose regimen are 45, 125, and 250 mg CVN766 for multiple-dose cohorts M1 through M3, respectively. Each multiple-dose cohort will consist of 8 participants randomized to CVN766 or placebo, whereby 6 participants will receive a daily oral dose of CVN766, and 2 participants will receive a matching placebo for 7 days. Dosing will be administered in the fasting state; this can be changed by the SRG if exposure is found to be higher in the fed state. The planned dosing duration for the multiple-dose cohorts is 7 days. However, the duration may be increased to ≤14 days at the discretion of the SRG if preliminary PK data suggests steady-state will not be achieved within 6 days of daily dosing. For each dose on intensive PK sampling days (first and last days of dosing, e.g., Days 1 and 7), participants will remain fasted for 4 hours post-dose. On other dosing days (Days 2-6), participants will remain fasted for 1-hour post-dose. Consumption of water is permitted as desired except for 1 hour before and after administration of Study Drug. Unlike the single-dose regimen, sentinel dosing within cohorts is not required in the multiple-dose regimen. Initiation of the multiple-dose regimen will only occur after a full blinded review of all safety, tolerability, and clinical laboratory results for the fasting drug administration to single-dose Cohort S3 (minimally including samples collected through Day 4) and available PK data. For each multiple-dose cohort after the first, the actual choice of dose level may be modified by the SRG after the available blinded safety, tolerability, clinical laboratory results, and PK data in the preceding multiple-dose and corresponding single-dose cohorts (i.e., multiple-dose Cohort M2 will not initiate until the data review for multiple-dose Cohort M1 and single-dose cohort S4 is complete). Each subsequent dose level may be higher, lower, or remain the same as the preceding. Additional multiple-dose cohort(s) may be added if deemed necessary by the SRG to fully characterize the safety and tolerability of CVN766. Such additional cohorts will follow the same schedule of events as for prior multiple-dose cohorts. Additional/alternative PK timepoints may be implemented if the SRG determines this is necessary to fully characterize the PK profile of CVN766. Participants for all multiple-dose cohorts will be admitted to the study unit 1 day prior to dosing and remain in the unit for the duration of the dosing period and for at least 48 hours after the last dose for safety and PK assessments before discharge. On treatment Days 1 and 7, participants will undergo safety monitoring and PK sampling from blood plasma through 48 hours post-dose and, in cohort M1 only, from urine through 24 hours post-dose. In cohorts M1 and M2, on treatment Day 7 (or last day of dosing, if extended beyond Day 7), participants will undergo additional PK sampling from CSF via lumbar puncture at 3 hours post-dose. If necessary to resolve questions arising from prior cohorts' data, participants in cohort M3 may also, at SRG discretion, undergo PK sampling from CSF via lumbar puncture, with the choice of day (e.g., Day 1 or Day 7) and sampling time to be decided by SRG. Participants in MAD cohorts may be asked to return to the clinic for an additional PK sample 3 days after the last dose (e.g., Day 10) depending on emerging PK data, (i.e., t½). The total confinement period will be 9 nights unless extended for additional dosing days or management of AEs. Follow-up assessments will occur approximately 7 and 14 days after the final dose.
Interventions
DRUGCVN766
highly selective orexin-1 receptor (Ox1R) antagonist
Sponsors
Cerevance
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Double-blind. placebo-controlled.
Intervention model description
For the single-dose regimen, approximately 40 healthy male or female participants will be enrolled in 1 of 5 single-dose cohorts (designated as S1 through S5, respectively) in an ascending fashion. Each cohort will consist of 8 participants randomized to CVN766 or placebo, whereby 6 participants will receive a single oral dose of CVN766 suspension, and 2 participants will receive a matching placebo suspension under overnight fasted conditions. For the multiple-dose regimen, approximately 24 healthy male and female participants age 18 to 50 years old will be enrolled in 1 of the 3 multiple-dose cohorts (designated as M1 through M3, respectively) in an ascending fashion. The dose levels planned to be studied in the multiple-dose regimen are 45, 125, and 250 mg CVN766 for multiple-dose cohorts M1 through M3, respectively.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Participant eligibility is determined according to the following criteria prior to entry into the study: 1. In the investigator's opinion, the participant can understand and sign the Informed Consent Form and comply with all protocol requirements. 2. The participant is a healthy male or female adult who is 18 to 55 years of age, inclusive at the time of ICF. 3. Participant weighs at least 45 kg (99 lbs) and has a BMI between 18.0 and 32.0 kg/m2, inclusive at Screening. 4. A male participant who is nonsterilized\* and sexually active with a female partner of childbearing potential\* agrees to use adequate contraception\* from signing the ICF throughout the study and for 12 weeks after the last dose. \*Definitions and acceptable methods of contraception are defined in Section 9.1.9 Contraception and Pregnancy Avoidance Procedure, and reporting responsibilities are defined in Section 9.1.10 Pregnancy. 5. A female participant of childbearing potential who complies with contraception requirements\* or a female with no childbearing potential, defined as the participant has been surgically sterilized (hysterectomy, bilateral oophorectomy, or tubal ligation) or who are postmenopausal (defined as continuous amenorrhea of at least 2 years and FSH\>40 IU/L).
Exclusion criteria
Any participant who meets any of the following criteria will not qualify for entry into the study: 1. Participant has received any investigational compound within 30 days prior to the first dose of study medication or within 5 half-lives, whichever is greater. 2. Participant is a study site employee or an immediate family member of a study site employee. 3. Participant has evidence of CS neurologic, cardiovascular, pulmonary, hepatic, hematopoietic disease, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease, serious allergy, full-body allergic skin rash (including hives), psychiatric disorder, or other abnormality that may impact the ability of the participant to participate or potentially confound the study results. 4. There is any finding in the participant's medical history, physical examination, or safety laboratory tests giving reasonable suspicion of a disease that would contraindicate taking CVN766 or a similar drug in the same class or that might interfere with the conduct of the study. 5. Participant has a known hypersensitivity to any component of the formulation of CVN766. 6. Participant has a positive urine result for drugs of abuse at Screening or Inpatient Check-in (Day -1). 7. Participant has a history of drug abuse or a history of alcohol abuse (more than 14 units/week) within 1 year prior to the Screening Visit or is unwilling to agree to abstain from alcohol and drugs throughout the study. 8. Participant has taken any excluded medication, supplements, or food products listed in the Excluded Medications and Dietary Products table as listed in Table 3: Excluded Medications and Dietary Products. 9. Male participants who do not agree to all the following rules: when sexually active with a female partner(s) of childbearing potential during the study, and for 12 weeks after the last dose of study drug: a) must use an acceptable method of birth control (condom or surgical sterilization) and b) refrain from sexual activity with female partners who do not use an acceptable method of birth control. Barrier contraception (condom) must be used by all-male participants who were not surgically sterilized at least 90 days prior to screening. Male participants must also agree to refrain from sperm donation during the study and until 12 weeks after the last dose of study drug. 10. Female participants who are pregnant or breastfeeding or plan to become pregnant or donate ova during the study or 30 days after the last dose of the study drug. Women of childbearing potential must agree to practice an acceptable method of birth control (e.g., oral or parenteral contraceptives, intrauterine device, barrier, abstinence). \*Definitions and acceptable methods of contraception are defined in Section 9.1.9, Contraception and Pregnancy Avoidance Procedure, and reporting responsibilities are defined in Section 9.1.10, Pregnancy. 11. Participant has previously had a seizure or convulsion (lifetime, with the exception of febrile seizures), including absence seizure. 12. Participant has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (i.e., a history of malabsorption, any surgical intervention known to impact absorption \[e.g., bariatric surgery or bowel resection\], esophageal reflux, peptic ulcer disease, erosive esophagitis, or frequent \[i.e., more than once per week\] occurrence of heartburn). 13. Participant has a history of cancer or other malignancy, except for basal cell carcinoma or squamous cell carcinoma that has been in remission for at least 3 years prior to Day 1. 14. Participant has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or a human immunodeficiency virus infection at Screening. 15. Participant who regularly use nicotine-containing products (including but not limited to cigarettes, electronic cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum). Casual user may participate but must agree to refrain from the time of Screening through the duration of the study or a positive urine cotinine test at Inpatient Check-in (Day 1). 16. Participant has poor peripheral venous access (defined as more than three failed attempts to cannulate). 17. Participant has donated or lost 450 mL or more of their blood volume (including plasmapheresis) or had a transfusion of any blood product within 45 days prior to Day 1. 18. Participant has an abnormal (CS) ECG at Screening or Inpatient Check-in (Day -1). Entry of any participant with an abnormal (NCS) ECG must be approved and documented by signature by the Investigator or medically qualified sub-investigator. 19. Participant has a supine blood pressure outside the ranges of 90 to 140 mm Hg for systolic and 40 to 90 mm Hg for diastolic, confirmed with repeat per PI discretion, at the Screening Visit or Inpatient Check-in (Day -1). 20. Participant has a resting heart rate outside the range of 40 to 100 bpm, confirmed with repeat per PI discretion, at the Screening Visit or Inpatient Check-in (Day -1). 21. Participant has a QT interval with Fridericia's correction method (QTcF) \>450 ms (males) or \>470 ms (females) or PR outside the range of 120 to 220 ms, confirmed with one repeat testing at the Screening Visit or Inpatient Check-in (Day -1) Visit. 22. Participant has abnormal Screening or Inpatient Check-in (Day -1) laboratory values that suggest a CS underlying disease or participant with the following lab abnormalities: ALT and/or AST \>1.5 the ULN, confirmed with one repeat testing. 23. Participant has a risk of suicide according to the investigator's clinical judgment or has made a suicide attempt in the previous 2 years.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) | Up to Day 14 | An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as any AE with onset occurring within 30 days (onset date - last date of dose + 1 ≤30) after study drug administration. Percentage of participants reporting at least one TEAE has been presented. |
| Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters | Up to Day 14 | Blood and urine samples were collected for the analysis of laboratory parameters including clinical chemistry, hematology, and urinalysis. The investigator was responsible for reviewing laboratory results for clinically significant abnormalities. |
| Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings | Up to Day 14 | 12-lead ECG recordings including heart rate and measured PR, QRS, QT, QT interval with Fridericia's correction method (QTcF) and QT interval with Bazett's correction method (QTcB) intervals. 12-lead ECG recordings were obtained after the participants have rested for at least 5 minutes in supine position. The investigator was responsible for reviewing laboratory results for clinically significant abnormalities. |
| Percentage of Participants With Clinically Significant Abnormal Vital Signs | Up to Day 14 | Vital signs including blood pressure (systolic and diastolic blood pressure), pulse rate, body temperature, respiratory rate and weight were measured after the participants have rested for at least 5 minutes in supine position. The investigator was responsible for reviewing laboratory results for clinically significant abnormalities. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | At Days 1, 2, 3, 4, 5 and 6 | Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| Cmax After Repeat Dose Administration of CVN766 | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, and 24 (Day 2 predose) hours postdose at Day 1 | Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| AUC From Time 0 to the End of Dosing Interval (AUCtau) After Repeat Dose Administration of CVN766 | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7 | Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| T1/2z After Repeat Dose Administration of CVN766 | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7 | Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| Accumulation Ratio (Rac) of Cmax After Repeat Dose Administration of CVN766 | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7 | Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. Rac (Cmax) was calculated as steady state Cmax at Day 7 divided by Cmax Day 1. |
| Time to Maximum Plasma Concentration (Cmax) (Tmax) After Single Dose Administration of CVN766 | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 hours postdose at Day 1 | Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| Time to Reach Steady State of CVN766 Concentration in the Dosing Interval | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7 | Blood samples were collected at indicated time points for PK analysis of time to reach steady state of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| Steady State Cmax After Repeat Dose Administration of CVN766 | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7 | Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| Steady State Minimum Observed Plasma Concentration (Cmin) After Repeat Dose Administration of CVN766 | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7 | Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| Ratio of the CVN766 Concentration in Cerebrospinal Fluid (CSF) Versus the Plasma Concentration After Single Ascending Dose of CVN766 45 mg | At 3 hours post-dose | The CSF samples were collected at indicated time point for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| Ratio of the CVN766 Concentration in CSF vs the Plasma Concentration After Repeated Dose Administration of CVN766 | At 3 hours post-dose | The CSF samples were collected at indicated time point for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| Rac of AUC After Repeat Dose Administration of CVN766 | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7 | Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. Rac (AUC) was calculated as steady state AUC at Day 7 divided by AUC Day 1 |
| Area Under the Plasma Concentration-time Curve From Time 0 to 24 (AUC24) After Single Dose Administration of CVN766 | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16 and 24 hours postdose at Day 1 | Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC [0-infinity]) After Single Dose Administration of CVN766 | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 hours postdose at Day 1 | Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
| Terminal Elimination Half-life (t1/2z) After Single Dose Administration of CVN766 | Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 hours postdose at Day 1 | Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. |
Countries
Australia
Participant flow
Recruitment details
The study was conducted across 1 site in Australia.
Pre-assignment details
This was a randomized, double-blind, placebo-controlled, safety, tolerability and pharmacokinetic study of escalating single ascending dose (SAD) and multiple ascending doses (MAD) of CVN766 in Healthy participants. Participants were randomized 6:1 (SAD) and 6:2 (MAD) to CVN766 or placebo.
Participants by arm
| Arm | Count |
|---|---|
| SAD CVN766 5 mg Participants were randomized to receive a single dose of 1 mg CVN766 oral suspension under overnight fasted condition. Participants remained fasted for 4 hours post dose. | 6 |
| SAD CVN766 15 mg Participants were randomized to receive a single dose of 15 mg CVN766 oral suspension under overnight fasted condition. Participants remained fasted for 4 hours post dose. | 6 |
| SAD CVN766 45 mg Participants were randomized to receive a single dose of 45 mg CVN766 oral suspension under overnight fasted condition. Participants remained fasted for 4 hours post dose. | 6 |
| SAD CVN766 125 mg Participants were randomized to receive a single dose of 125 mg CVN766 oral suspension under overnight fasted condition. Participants remained fasted for 4 hours post dose. | 6 |
| SAD CVN766 250 mg Participants were randomized to receive a single dose of 250 mg CVN766 oral suspension under overnight fasted condition. Participants remained fasted for 4 hours post dose. | 6 |
| SAD Placebo Participants were randomized to receive a single dose of matching placebo oral suspension under overnight fasted condition. Participants remained fasted for 4 hours post dose. | 10 |
| MAD CVN766 45 mg Participants were randomized to receive a daily dose of 45 mg CVN766 oral suspension in fasting or fed state for 7 days, which was determined by the Safety Review Group (SRG). | 6 |
| MAD CVN766 125 mg Participants were randomized to receive a daily dose of 125 mg CVN766 oral suspension in fasting or fed state for 7 days, which was determined by the SRG. | 6 |
| MAD CVN766 250 mg Participants were randomized to receive a daily dose of 250 mg CVN766 oral suspension in fasting or fed state for 7 days, which was determined by the SRG. | 6 |
| MAD Placebo Participants were randomized to receive a daily dose of matching placebo oral suspension in fasting or fed state for 7 days, which was determined by the SRG. | 6 |
| Total | 64 |
Baseline characteristics
| Characteristic | SAD CVN766 15 mg | Total | MAD Placebo | MAD CVN766 250 mg | MAD CVN766 125 mg | MAD CVN766 45 mg | SAD CVN766 5 mg | SAD Placebo | SAD CVN766 250 mg | SAD CVN766 125 mg | SAD CVN766 45 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 30.8 Years STANDARD_DEVIATION 7.4 | 30.2 Years STANDARD_DEVIATION 8.1 | 26.8 Years STANDARD_DEVIATION 4.8 | 31.5 Years STANDARD_DEVIATION 8.1 | 27.5 Years STANDARD_DEVIATION 7.6 | 37.2 Years STANDARD_DEVIATION 7.5 | 29.5 Years STANDARD_DEVIATION 5.3 | 31.9 Years STANDARD_DEVIATION 13.3 | 26.8 Years STANDARD_DEVIATION 3.8 | 26.8 Years STANDARD_DEVIATION 6.5 | 29.8 Years STANDARD_DEVIATION 6.4 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 6 Participants | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 55 Participants | 5 Participants | 6 Participants | 4 Participants | 5 Participants | 4 Participants | 10 Participants | 5 Participants | 5 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 3 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 2 Participants | 19 Participants | 2 Participants | 2 Participants | 2 Participants | 2 Participants | 0 Participants | 4 Participants | 2 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized Black or African American | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Indigenous Australian or Torres Strait Islander | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Other, Mixed White Indigenous Australian | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White | 3 Participants | 41 Participants | 4 Participants | 4 Participants | 4 Participants | 4 Participants | 4 Participants | 6 Participants | 3 Participants | 5 Participants | 4 Participants |
| Sex: Female, Male Female | 0 Participants | 19 Participants | 2 Participants | 1 Participants | 3 Participants | 1 Participants | 3 Participants | 5 Participants | 3 Participants | 1 Participants | 0 Participants |
| Sex: Female, Male Male | 6 Participants | 45 Participants | 4 Participants | 5 Participants | 3 Participants | 5 Participants | 3 Participants | 5 Participants | 3 Participants | 5 Participants | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 10 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 |
| other Total, other adverse events | 3 / 6 | 2 / 6 | 5 / 6 | 1 / 6 | 4 / 6 | 5 / 10 | 4 / 6 | 2 / 6 | 4 / 6 | 2 / 6 |
| serious Total, serious adverse events | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 10 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 |
Outcome results
Primary
Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as any AE with onset occurring within 30 days (onset date - last date of dose + 1 ≤30) after study drug administration. Percentage of participants reporting at least one TEAE has been presented.
Time frame: Up to Day 14
Population: Safety Population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SAD CVN766 5 mg | Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) | 50.0 Percentage of participants |
| SAD CVN766 15 mg | Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) | 33.3 Percentage of participants |
| SAD CVN766 45 mg | Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) | 83.3 Percentage of participants |
| SAD CVN766 125 mg | Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) | 16.7 Percentage of participants |
| SAD CVN766 250 mg | Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) | 66.7 Percentage of participants |
| SAD Placebo | Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) | 50.0 Percentage of participants |
| MAD CVN766 45 mg | Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) | 66.7 Percentage of participants |
| MAD CVN766 125 mg | Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) | 33.3 Percentage of participants |
| MAD CVN766 250 mg | Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) | 66.7 Percentage of participants |
| MAD Placebo | Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) | 33.3 Percentage of participants |
Primary
Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters
Blood and urine samples were collected for the analysis of laboratory parameters including clinical chemistry, hematology, and urinalysis. The investigator was responsible for reviewing laboratory results for clinically significant abnormalities.
Time frame: Up to Day 14
Population: Safety Population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SAD CVN766 5 mg | Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters | 0 Percentage of participants |
| SAD CVN766 15 mg | Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters | 0 Percentage of participants |
| SAD CVN766 45 mg | Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters | 0 Percentage of participants |
| SAD CVN766 125 mg | Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters | 0 Percentage of participants |
| SAD CVN766 250 mg | Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters | 0 Percentage of participants |
| SAD Placebo | Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters | 0 Percentage of participants |
| MAD CVN766 45 mg | Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters | 0 Percentage of participants |
| MAD CVN766 125 mg | Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters | 0 Percentage of participants |
| MAD CVN766 250 mg | Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters | 0 Percentage of participants |
| MAD Placebo | Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters | 0 Percentage of participants |
Primary
Percentage of Participants With Clinically Significant Abnormal Vital Signs
Vital signs including blood pressure (systolic and diastolic blood pressure), pulse rate, body temperature, respiratory rate and weight were measured after the participants have rested for at least 5 minutes in supine position. The investigator was responsible for reviewing laboratory results for clinically significant abnormalities.
Time frame: Up to Day 14
Population: Safety Population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SAD CVN766 5 mg | Percentage of Participants With Clinically Significant Abnormal Vital Signs | 0 Percentage of participants |
| SAD CVN766 15 mg | Percentage of Participants With Clinically Significant Abnormal Vital Signs | 0 Percentage of participants |
| SAD CVN766 45 mg | Percentage of Participants With Clinically Significant Abnormal Vital Signs | 0 Percentage of participants |
| SAD CVN766 125 mg | Percentage of Participants With Clinically Significant Abnormal Vital Signs | 0 Percentage of participants |
| SAD CVN766 250 mg | Percentage of Participants With Clinically Significant Abnormal Vital Signs | 0 Percentage of participants |
| SAD Placebo | Percentage of Participants With Clinically Significant Abnormal Vital Signs | 0 Percentage of participants |
| MAD CVN766 45 mg | Percentage of Participants With Clinically Significant Abnormal Vital Signs | 0 Percentage of participants |
| MAD CVN766 125 mg | Percentage of Participants With Clinically Significant Abnormal Vital Signs | 0 Percentage of participants |
| MAD CVN766 250 mg | Percentage of Participants With Clinically Significant Abnormal Vital Signs | 0 Percentage of participants |
| MAD Placebo | Percentage of Participants With Clinically Significant Abnormal Vital Signs | 0 Percentage of participants |
Primary
Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings
12-lead ECG recordings including heart rate and measured PR, QRS, QT, QT interval with Fridericia's correction method (QTcF) and QT interval with Bazett's correction method (QTcB) intervals. 12-lead ECG recordings were obtained after the participants have rested for at least 5 minutes in supine position. The investigator was responsible for reviewing laboratory results for clinically significant abnormalities.
Time frame: Up to Day 14
Population: Safety Population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SAD CVN766 5 mg | Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings | 0 Percentage of participants |
| SAD CVN766 15 mg | Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings | 0 Percentage of participants |
| SAD CVN766 45 mg | Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings | 0 Percentage of participants |
| SAD CVN766 125 mg | Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings | 0 Percentage of participants |
| SAD CVN766 250 mg | Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings | 0 Percentage of participants |
| SAD Placebo | Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings | 0 Percentage of participants |
| MAD CVN766 45 mg | Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings | 0 Percentage of participants |
| MAD CVN766 125 mg | Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings | 0 Percentage of participants |
| MAD CVN766 250 mg | Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings | 0 Percentage of participants |
| MAD Placebo | Percentage of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings | 0 Percentage of participants |
Secondary
Accumulation Ratio (Rac) of Cmax After Repeat Dose Administration of CVN766
Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. Rac (Cmax) was calculated as steady state Cmax at Day 7 divided by Cmax Day 1.
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7
Population: PK Population.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | Accumulation Ratio (Rac) of Cmax After Repeat Dose Administration of CVN766 | 1.390 Ratio | Geometric Coefficient of Variation 13.7 |
| SAD CVN766 15 mg | Accumulation Ratio (Rac) of Cmax After Repeat Dose Administration of CVN766 | 1.528 Ratio | Geometric Coefficient of Variation 41.7 |
| SAD CVN766 45 mg | Accumulation Ratio (Rac) of Cmax After Repeat Dose Administration of CVN766 | 1.588 Ratio | Geometric Coefficient of Variation 33.7 |
Secondary
Area Under the Plasma Concentration-time Curve From Time 0 to 24 (AUC24) After Single Dose Administration of CVN766
Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16 and 24 hours postdose at Day 1
Population: PK Population.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | Area Under the Plasma Concentration-time Curve From Time 0 to 24 (AUC24) After Single Dose Administration of CVN766 | 319.904 Hours*nanograms per milliliter | Geometric Coefficient of Variation 25 |
| SAD CVN766 15 mg | Area Under the Plasma Concentration-time Curve From Time 0 to 24 (AUC24) After Single Dose Administration of CVN766 | 2155.879 Hours*nanograms per milliliter | Geometric Coefficient of Variation 31.6 |
| SAD CVN766 45 mg | Area Under the Plasma Concentration-time Curve From Time 0 to 24 (AUC24) After Single Dose Administration of CVN766 | 4001.523 Hours*nanograms per milliliter | Geometric Coefficient of Variation 37 |
| SAD CVN766 125 mg | Area Under the Plasma Concentration-time Curve From Time 0 to 24 (AUC24) After Single Dose Administration of CVN766 | 10990.192 Hours*nanograms per milliliter | Geometric Coefficient of Variation 72.1 |
| SAD CVN766 250 mg | Area Under the Plasma Concentration-time Curve From Time 0 to 24 (AUC24) After Single Dose Administration of CVN766 | 15607.247 Hours*nanograms per milliliter | Geometric Coefficient of Variation 36.1 |
Secondary
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC [0-infinity]) After Single Dose Administration of CVN766
Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 hours postdose at Day 1
Population: PK Population.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC [0-infinity]) After Single Dose Administration of CVN766 | 322.066 Hours*nanograms per milliliter | Geometric Coefficient of Variation 25.7 |
| SAD CVN766 15 mg | Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC [0-infinity]) After Single Dose Administration of CVN766 | 2414.049 Hours*nanograms per milliliter | Geometric Coefficient of Variation 43.4 |
| SAD CVN766 45 mg | Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC [0-infinity]) After Single Dose Administration of CVN766 | 4260.722 Hours*nanograms per milliliter | Geometric Coefficient of Variation 37.2 |
| SAD CVN766 125 mg | Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC [0-infinity]) After Single Dose Administration of CVN766 | 13527.110 Hours*nanograms per milliliter | Geometric Coefficient of Variation 98.9 |
| SAD CVN766 250 mg | Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC [0-infinity]) After Single Dose Administration of CVN766 | 19573.857 Hours*nanograms per milliliter | Geometric Coefficient of Variation 39.4 |
Secondary
AUC From Time 0 to the End of Dosing Interval (AUCtau) After Repeat Dose Administration of CVN766
Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7
Population: PK Population.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | AUC From Time 0 to the End of Dosing Interval (AUCtau) After Repeat Dose Administration of CVN766 | 5523.759 Hours*nanograms per milliliter | Geometric Coefficient of Variation 39.3 |
| SAD CVN766 15 mg | AUC From Time 0 to the End of Dosing Interval (AUCtau) After Repeat Dose Administration of CVN766 | 18712.219 Hours*nanograms per milliliter | Geometric Coefficient of Variation 45.8 |
| SAD CVN766 45 mg | AUC From Time 0 to the End of Dosing Interval (AUCtau) After Repeat Dose Administration of CVN766 | 42303.478 Hours*nanograms per milliliter | Geometric Coefficient of Variation 49.5 |
Secondary
Cmax After Repeat Dose Administration of CVN766
Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, and 24 (Day 2 predose) hours postdose at Day 1
Population: PK Population.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | Cmax After Repeat Dose Administration of CVN766 | 534.420 Nanograms per milliliter | Geometric Coefficient of Variation 19.8 |
| SAD CVN766 15 mg | Cmax After Repeat Dose Administration of CVN766 | 1309.959 Nanograms per milliliter | Geometric Coefficient of Variation 30.6 |
| SAD CVN766 45 mg | Cmax After Repeat Dose Administration of CVN766 | 2398.089 Nanograms per milliliter | Geometric Coefficient of Variation 38.6 |
Secondary
Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766
Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: At Days 1, 2, 3, 4, 5 and 6
Population: PK Population. Only those participants with data available at specified time points have been presented.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| SAD CVN766 5 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 1 | 32.443 Nanograms per milliliter | Geometric Coefficient of Variation 94 |
| SAD CVN766 5 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 2 | 47.839 Nanograms per milliliter | Geometric Coefficient of Variation 90.2 |
| SAD CVN766 5 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 3 | 65.131 Nanograms per milliliter | Geometric Coefficient of Variation 65 |
| SAD CVN766 5 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 4 | 61.883 Nanograms per milliliter | Geometric Coefficient of Variation 59.3 |
| SAD CVN766 5 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 5 | 75.024 Nanograms per milliliter | Geometric Coefficient of Variation 55.5 |
| SAD CVN766 5 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 6 | 81.352 Nanograms per milliliter | Geometric Coefficient of Variation 76.5 |
| SAD CVN766 15 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 6 | 359.249 Nanograms per milliliter | Geometric Coefficient of Variation 83.3 |
| SAD CVN766 15 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 1 | 208.061 Nanograms per milliliter | Geometric Coefficient of Variation 60.4 |
| SAD CVN766 15 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 4 | 325.191 Nanograms per milliliter | Geometric Coefficient of Variation 76 |
| SAD CVN766 15 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 5 | 330.735 Nanograms per milliliter | Geometric Coefficient of Variation 85.3 |
| SAD CVN766 15 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 2 | 278.564 Nanograms per milliliter | Geometric Coefficient of Variation 75 |
| SAD CVN766 15 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 3 | 298.945 Nanograms per milliliter | Geometric Coefficient of Variation 74.2 |
| SAD CVN766 45 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 2 | 856.904 Nanograms per milliliter | Geometric Coefficient of Variation 75.1 |
| SAD CVN766 45 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 3 | 1002.607 Nanograms per milliliter | Geometric Coefficient of Variation 98.8 |
| SAD CVN766 45 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 6 | 1068.025 Nanograms per milliliter | Geometric Coefficient of Variation 82.9 |
| SAD CVN766 45 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 4 | 1058.768 Nanograms per milliliter | Geometric Coefficient of Variation 108.5 |
| SAD CVN766 45 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 1 | 605.924 Nanograms per milliliter | Geometric Coefficient of Variation 68.1 |
| SAD CVN766 45 mg | Maximum Observed Trough Concentrations After Repeat Dose Administration of CVN766 | Day 5 | 1075.797 Nanograms per milliliter | Geometric Coefficient of Variation 96.7 |
Secondary
Rac of AUC After Repeat Dose Administration of CVN766
Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis. Rac (AUC) was calculated as steady state AUC at Day 7 divided by AUC Day 1
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7
Population: PK Population.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | Rac of AUC After Repeat Dose Administration of CVN766 | 1.627 Ratio | Geometric Coefficient of Variation 25.6 |
| SAD CVN766 15 mg | Rac of AUC After Repeat Dose Administration of CVN766 | 1.517 Ratio | Geometric Coefficient of Variation 49.3 |
| SAD CVN766 45 mg | Rac of AUC After Repeat Dose Administration of CVN766 | 1.771 Ratio | Geometric Coefficient of Variation 28.8 |
Secondary
Ratio of the CVN766 Concentration in Cerebrospinal Fluid (CSF) Versus the Plasma Concentration After Single Ascending Dose of CVN766 45 mg
The CSF samples were collected at indicated time point for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: At 3 hours post-dose
Population: PK Population.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | Ratio of the CVN766 Concentration in Cerebrospinal Fluid (CSF) Versus the Plasma Concentration After Single Ascending Dose of CVN766 45 mg | 11.558 Unitless | Geometric Coefficient of Variation 31.7 |
Secondary
Ratio of the CVN766 Concentration in CSF vs the Plasma Concentration After Repeated Dose Administration of CVN766
The CSF samples were collected at indicated time point for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: At 3 hours post-dose
Population: PK Population.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | Ratio of the CVN766 Concentration in CSF vs the Plasma Concentration After Repeated Dose Administration of CVN766 | 13.083 Unitless | Geometric Coefficient of Variation 25.9 |
Secondary
Steady State Cmax After Repeat Dose Administration of CVN766
Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7
Population: PK Population
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | Steady State Cmax After Repeat Dose Administration of CVN766 | 742.582 Nanograms per milliliter | Geometric Coefficient of Variation 14.8 |
| SAD CVN766 15 mg | Steady State Cmax After Repeat Dose Administration of CVN766 | 2001.021 Nanograms per milliliter | Geometric Coefficient of Variation 32.9 |
| SAD CVN766 45 mg | Steady State Cmax After Repeat Dose Administration of CVN766 | 3807.481 Nanograms per milliliter | Geometric Coefficient of Variation 33.2 |
Secondary
Steady State Minimum Observed Plasma Concentration (Cmin) After Repeat Dose Administration of CVN766
Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7
Population: PK Population. Only those participants with data available at specified time points have been presented.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | Steady State Minimum Observed Plasma Concentration (Cmin) After Repeat Dose Administration of CVN766 | 77.760 Nanograms per milliliter | Geometric Coefficient of Variation 74.5 |
| SAD CVN766 15 mg | Steady State Minimum Observed Plasma Concentration (Cmin) After Repeat Dose Administration of CVN766 | 315.991 Nanograms per milliliter | Geometric Coefficient of Variation 89.7 |
| SAD CVN766 45 mg | Steady State Minimum Observed Plasma Concentration (Cmin) After Repeat Dose Administration of CVN766 | 1042.811 Nanograms per milliliter | Geometric Coefficient of Variation 79 |
Secondary
T1/2z After Repeat Dose Administration of CVN766
Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7
Population: PK Population.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | T1/2z After Repeat Dose Administration of CVN766 | 7.7710 hours | Standard Deviation 3.20745 |
| SAD CVN766 15 mg | T1/2z After Repeat Dose Administration of CVN766 | 10.9721 hours | Standard Deviation 6.76714 |
| SAD CVN766 45 mg | T1/2z After Repeat Dose Administration of CVN766 | 12.1702 hours | Standard Deviation 4.47362 |
Secondary
Terminal Elimination Half-life (t1/2z) After Single Dose Administration of CVN766
Blood samples were collected at indicated time points for PK analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 hours postdose at Day 1
Population: PK Population.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SAD CVN766 5 mg | Terminal Elimination Half-life (t1/2z) After Single Dose Administration of CVN766 | 2.9625 hours | Standard Deviation 0.92895 |
| SAD CVN766 15 mg | Terminal Elimination Half-life (t1/2z) After Single Dose Administration of CVN766 | 7.3485 hours | Standard Deviation 4.57313 |
| SAD CVN766 45 mg | Terminal Elimination Half-life (t1/2z) After Single Dose Administration of CVN766 | 5.7745 hours | Standard Deviation 2.11356 |
| SAD CVN766 125 mg | Terminal Elimination Half-life (t1/2z) After Single Dose Administration of CVN766 | 11.4565 hours | Standard Deviation 10.57028 |
| SAD CVN766 250 mg | Terminal Elimination Half-life (t1/2z) After Single Dose Administration of CVN766 | 8.6156 hours | Standard Deviation 1.75924 |
Secondary
Time to Maximum Plasma Concentration (Cmax) (Tmax) After Single Dose Administration of CVN766
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 hours postdose at Day 1
Population: PK Population: included all participants who received study drug and had at least 1 measurable plasma concentration.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| SAD CVN766 5 mg | Time to Maximum Plasma Concentration (Cmax) (Tmax) After Single Dose Administration of CVN766 | 0.9165 hours |
| SAD CVN766 15 mg | Time to Maximum Plasma Concentration (Cmax) (Tmax) After Single Dose Administration of CVN766 | 1.0000 hours |
| SAD CVN766 45 mg | Time to Maximum Plasma Concentration (Cmax) (Tmax) After Single Dose Administration of CVN766 | 1.0000 hours |
| SAD CVN766 125 mg | Time to Maximum Plasma Concentration (Cmax) (Tmax) After Single Dose Administration of CVN766 | 1.5000 hours |
| SAD CVN766 250 mg | Time to Maximum Plasma Concentration (Cmax) (Tmax) After Single Dose Administration of CVN766 | 1.5000 hours |
Secondary
Time to Reach Steady State of CVN766 Concentration in the Dosing Interval
Blood samples were collected at indicated time points for PK analysis of time to reach steady state of CVN766. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Predose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, 48, and 72 a hours postdose at Day 7
Population: PK Population. Only those participants with data available at specified time points have been presented.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| SAD CVN766 5 mg | Time to Reach Steady State of CVN766 Concentration in the Dosing Interval | Tmin, ss | 24.0000 hours |
| SAD CVN766 5 mg | Time to Reach Steady State of CVN766 Concentration in the Dosing Interval | Tmax, ss | 1.2750 hours |
| SAD CVN766 5 mg | Time to Reach Steady State of CVN766 Concentration in the Dosing Interval | Tlast, ss | 42.0000 hours |
| SAD CVN766 15 mg | Time to Reach Steady State of CVN766 Concentration in the Dosing Interval | Tmin, ss | 24.0000 hours |
| SAD CVN766 15 mg | Time to Reach Steady State of CVN766 Concentration in the Dosing Interval | Tmax, ss | 2.0000 hours |
| SAD CVN766 15 mg | Time to Reach Steady State of CVN766 Concentration in the Dosing Interval | Tlast, ss | 48.0335 hours |
| SAD CVN766 45 mg | Time to Reach Steady State of CVN766 Concentration in the Dosing Interval | Tmax, ss | 1.7415 hours |
| SAD CVN766 45 mg | Time to Reach Steady State of CVN766 Concentration in the Dosing Interval | Tlast, ss | 73.2915 hours |
| SAD CVN766 45 mg | Time to Reach Steady State of CVN766 Concentration in the Dosing Interval | Tmin, ss | 20.0165 hours |